Indole Cytosolic Phospholipase A<sub>2</sub> α Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1<i>H</i>-indol-3-yl]propyl}benzoic Acid, Efipladib
作者:John C. McKew、Katherine L. Lee、Marina W. H. Shen、Paresh Thakker、Megan A. Foley、Mark L. Behnke、Baihua Hu、Fuk-Wah Sum、Steve Tam、Yonghan Hu、Lihren Chen、Steven J. Kirincich、Ronald Michalak、Jennifer Thomason、Manus Ipek、Kun Wu、Lane Wooder、Manjunath K. Ramarao、Elizabeth A. Murphy、Debra G. Goodwin、Leo Albert、Xin Xu、Frances Donahue、M. Sherry Ku、James Keith、Cheryl L. Nickerson-Nutter、William M. Abraham、Cara Williams、Martin Hegen、James D. Clark
DOI:10.1021/jm701467e
日期:2008.6.1
The optimization of a class of indole cPLA 2 alpha inhibitors is described herein. The importance of the substituent at C3 and the substitution pattern of the phenylmethane sulfonamide region are highlighted. Optimization of these regions led to the discovery of 111 (efipladib) and 121 (WAY-196025), which are shown to be potent, selective inhibitors of cPLA 2 alpha in a variety of isolated enzyme assays
本文描述了一类吲哚cPLA 2α抑制剂的优化。突出了C 3处取代基的重要性和苯基甲烷磺酰胺区的取代方式。这些区域的优化导致发现111(efipladib)和121(WAY-196025),在各种分离的酶测定,基于细胞的测定以及大鼠和人类中,它们被证明是有效的cPLA 2α选择性抑制剂。全血检测。这些化合物的结合已使用等温滴定热法进一步检查。最后,当在多种急性和慢性前列腺素和白三烯依赖性的体内模型中口服给药时,这些化合物显示出功效。